RESEARCH MONOGRAPH · KDC-MN-089

Follistatin 344

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

53/100

Myostatin antagonist with massive preclinical hypertrophy effects and a sourcing nightmare that makes most commercial material suspect

Follistatin 344 is one of the two principal follistatin isoforms (the 344-residue form, FS-344, is the predominant circulating species; FS-315 is the longer alternative-splicing variant). Both bind and neutralize myostatin, GDF-11, activin A, and other TGF-beta superfamily ligands, which makes follistatin the most potent endogenous myostatin antagonist known.

What we like is the preclinical biology. Lee and McPherron's foundational work on myostatin in the 90s, plus the follistatin overexpression studies in mice and dogs from the Kambadur and the Khurana groups, demonstrated genuinely striking muscle hypertrophy effects: 30-50% increases in muscle mass with sustained follistatin expression, plus improvements in muscle function in Duchenne muscular dystrophy mouse models. The Acceleron clinical work on related TGF-beta superfamily antagonists (sotatercept, luspatercept) eventually produced approved drugs in non-muscle indications, validating the broader pharmacology.

What we dont like is everything about translating to peripheral protein administration. The preclinical hypertrophy data is mostly from gene therapy or transgenic overexpression studies, not from subcutaneous follistatin protein injection. Recombinant follistatin protein has poor serum stability, IGFBP-like binding to its target ligands creates complex pharmacokinetics, and the small clinical trials that have been attempted (the BMN-152 program in DMD, for instance) didnt show the hypertrophy magnitudes the preclinical work suggested. The Acceleron approach used Fc-fused activin receptor decoys instead, which is mechanistically related but pharmacologically distinct.

Sourcing is the genuine disaster. Follistatin 344 is a 344-residue glycoprotein with multiple disulfide bonds, and proper folding plus glycosylation are essential for activity. Bacterial expression systems produce inactive material; only mammalian or insect cell expression gives biologically active recombinant follistatin. Most "follistatin 344" in the research peptide market is either incorrectly folded, truncated, or just labeled wrong. Bioactivity testing (myostatin neutralization assay) is essentially mandatory and almost no commercial suppliers provide it.

For mechanistic research on follistatin biology, sourcing from established academic suppliers like R&D Systems or Peprotech is the only realistic path. The peptide-market follistatin 344 is mostly unreliable. The compound has interesting biology but the practical research utility is severely sourcing-limited.

Evidence: 55
Mechanism: 75
Reliability: 50
Safety: 55
Sourcing: 35
Value: 40
Signal: 60
Staying power: 55

Plain-language summary Intrigue 75 / 100

Follistatin-344 is a 344-amino-acid form of follistatin, a protein that binds and inactivates myostatin (the muscle-growth brake). Used in research for muscle hypertrophy studies. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Myostatin antagonist / follistatin isoform

An isoform of the endogenous myostatin antagonist follistatin, sold as a research peptide for muscle hypertrophy applications.

Abstract

Follistatin 344 is an isoform of the endogenous protein follistatin (the 344-residue form, encoded as one splice variant of the FST gene). Follistatin binds and antagonizes myostatin (GDF-8), a TGF-beta family member that negatively regulates skeletal muscle mass. Antagonizing myostatin produces increased muscle hypertrophy and reduced muscle atrophy in animal models. Follistatin 344 is sold as a research peptide for muscle development applications. The compound is administered subcutaneously or intramuscularly; oral bioavailability is poor. There is no human clinical trial record for follistatin 344 specifically; the related ACE-031 (a soluble activin receptor type IIB Fc fusion) was developed pharmaceutically and reached Phase 2. Investigational doses range widely with poorly characterized safety; chronic myostatin antagonism may have cardiac and tendon implications that are not adequately studied.

Mechanism of action

Endogenous myostatin (GDF-8) antagonist; binds and neutralizes myostatin to increase muscle hypertrophy.

Reported research dose ranges

100 micrograms to 1 mg SC/IM (reported research dose ranges in the literature); safety poorly characterized.

References

Lee SJ, McPherron AC. Regulation of myostatin activity and muscle growth. PNAS 2001.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-089

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Follistatin 344

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs